Glenmark posts strong FY26 results with 27.5% revenue jump

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term

Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity

The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit

Supreme Court declares right to trauma care part of Article 21 in landmark judgement

The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

Solvay and Pantys deepen partnership to expand menstrual health access

Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs

Morepen Labs posts strong Q4 FY26 net profit

For the full year, standalone gross revenue crossed Rs. 1,700 crore

Cadila Pharma launches Subhadra Syrup for menstrual health support

The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia

Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care

POSEIDON is among the largest global datasets to quantify this residual inflammatory burden